Cognitive decline in prodromal Huntington disease: Implications for clinical trials

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 11, 2013, Pages 1233-1239

  Paulsen, Jane S ^a   Smith, Megan M ^a   Long, Jeffrey D ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; CLINICAL RESEARCH; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DISEASE DURATION; EDUCATIONAL STATUS; FEMALE; GENDER; HUMAN; HUNTINGTON CHOREA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRODROMAL SYMPTOM;

EID: 84885649254     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-305114     Document Type: Article

References (46)

1. Paulsen JS. Early detection of Huntington's disease. Future Neurol 2010;5:85-104.
2. Paulsen JS, Hayden M, Stout JC, et al. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 2006;63:883-90. (Pubitemid 43882298)
3. Giordani B, Berent S, Boivin MJ, et al. Longitudinal neuropsychological and genetic linkage analysis of persons at risk for Huntington's disease. Arch Neurol 1995;52:59-64.
4. Campodonico JR, Codori AM, Brandt J. Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation. J Neurol Neurosurg Psychiatry 1996;61:621-4. (Pubitemid 27023342)
5. Witjes-Ane M-NW, Mertens B, van Vugt JPP, et al. Longitudinal evaluation of "Presymptomatic" carriers of Huntington's disease. J Neuropsychiatry Clin Neurosci 2007;19:310-17. (Pubitemid 47293905)
6. Stout JC, Jones R, Labuschagne I, et al. Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. J Neurol Neurosurg Psychiatry 2012;83:687-94.
7. Kirkwood SC, Siemers E, Hodes ME, et al. Subtle changes among presymptomatic carriers of the Huntington's disease gene. J Neurol Neurosurg Psychiatry 2000;69:773-9.
8. Paulsen JS, Zhao H, Stout JC, et al. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 2001;57:658-62. (Pubitemid 32782994)
9. Lemiere J, Decruyenaere M, Evers-Kiebooms G, et al. Longitudinal study evaluating neuropsychological changes in so-called asymptomatic carriers of the Huntington's disease mutation after 1 year. Acta Neurol Scand 2002;106:131-41.
10. Snowden JS, Craufurd D, Thompson J, et al. Psychomotor, executive, and memory function in preclinical Huntington's Disease. J Clin Exp Neuropsychol 2002;24:133-45. (Pubitemid 34496862)
11. Lemiere J, Decruyenaere M, Evers-Kiebooms G, et al. Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation-a longitudinal follow-up study. J Neurol 2004;251:935-42. (Pubitemid 39119311)
12. Brandt J, Inscore AB, Ward J, et al. Neuropsychological deficits in Huntington's disease gene carriers and correlates of early " conversion". J Neuropsychiatry Clin Neurosci 2008;20:466-72.
13. Solomon AC, Stout JC, Weaver M, et al. Ten-year rate of longitudinal change in neurocognitive and motor function in prediagnosis Huntington disease. Mov Disord 2008;23:1830-6.
14. Rupp J, Blekher T, Jackson J, et al. Progression in prediagnostic Huntington disease. J Neurol Neurosurg Psychiatry 2010;81:379-84.
15. Hart E, Middelkoop H, Jurgens CK, et al. Seven-year clinical follow-up of premanifest carriers of Huntington's disease. PLoS Curr 2011;3:RRN1288.
16. Maroof DA, Gross AL, Brandt J. Modeling longitudinal change in motor and cognitive processing speed in presymptomatic Huntington's disease. J Clin Exp Neuropsychol 2011;33:901-9.
17. Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10:31-42.
18. Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24. month observational data. Lancet Neurol 2012;11:42-53.
19. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebocontrolled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-45.
20. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41. (Pubitemid 36384100)
21. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007;64:633-47. (Pubitemid 46878665)
22. Buchanan RW, Freedman R, Javitt DC, et al. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 2007;33:1120-30. (Pubitemid 47347922)
23. Walker FO. Huntington's disease. Lancet 2007;369:218-28. (Pubitemid 46107685)
24. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-42.
25. Biglan KM, Ross CA, Langbehn DR, et al. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord 2009;24:1763-72.
26. Biglan KM, Zhang Y, Long JD, et al. Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front Aging Neurosci 2013;5:12.
27. Zhang Y, Long JD, Mills JA, et al. Indexing disease progression at study entry with individuals at-risk for Huntington Disease. Am J Med Genet B Neuropsychiatr Genet 2011;156:751-63.
28. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer, 2000.
29. Little RJA, Rubin DB. Statistical analysis with missing data. 2nd edn. New York: Wiley, 2002.
30. Akaike H. Information theory and an extension of the maximum likelihood principle. In: Petrov BN, Csaki F. eds. 2nd International Symposium on Information Theory; Budapest: Akademiai Kiado, 1973:267-81.
31. Altmann DR, Jasperse B, Barkhof F, et al. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology 2009;72:595-601.
32. Thompson JC, Poliakoff E, Sollom AC, et al. Automaticity and attention in Huntington's disease: when two hands are not better than one. Neuropsychologia 2010;48:171-8.
33. Aron AR, Watkins L, Sahakian BJ, et al. Task-set switching deficits in early-stage Huntington's disease: implications for basal ganglia function. J Cogn Neurosci 2003;15:629-42. (Pubitemid 36871877)
34. Lawrence AD, Sahakian BJ, Hodges JR, et al. Executive and mnemonic functions in early Huntington's disease. Brain 1996;119(Pt 5):1633-45. (Pubitemid 26375733)
35. O'Rourke JJ, Beglinger LJ, Smith MM, et al. The Trail Making Test in prodromal Huntington disease: contributions of disease progression to test performance. J Clin Exp Neuropsychol 2011;33:567-79.
36. Paulsen JS, Zimbelman JL, Hinton SC, et al. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease. AJNR Am J Neuroradiol 2004;25:1715-21. (Pubitemid 44123696)
37. Zimbelman JL, Paulsen JS, Mikos A, et al. fMRI detection of early neural dysfunction in preclinical Huntington's disease. J Int Neuropsychol Soc 2007;13:758-69. (Pubitemid 47299445)
38. Bostan AC, Strick PL. The cerebellum and basal ganglia are interconnected. Neuropsychol Rev 2010;20:261-70.
39. Harrington DL, Zimbelman JL, Hinton SC, et al. Neural modulation of temporal encoding, maintenance, and decision processes. Cereb Cortex 2010;20:1274-85.
40. Elsinger CL, Harrington DL, Rao SM. From preparation to online control: reappraisal of neural circuitry mediating internally generated and externally guided actions. Neuroimage 2006;31:1177-87. (Pubitemid 43851346)
41. Harrington DL, Smith MM, Zhang Y, et al. Cognitive domains that predict time to diagnosis in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2012;83:612-19.
42. Rao SM, Harrington DL, Haaland KY, et al. Distributed neural systems underlying the timing of movements. J Neurosci 1997;17:5528-35. (Pubitemid 27300317)
43. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357-81. (Pubitemid 16055790)
44. Bostan AC, Dum RP, Strick PL. The basal ganglia communicate with the cerebellum. Proc Natl Acad Sci USA 2010;107:8452-6.
45. Paulsen JS. Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep 2011;11:474-83.
46. Paulsen JS, Long JD. Neurodegenerative disease: establishing a clinical trial battery for Huntington disease. Nat Rev Neurol 2012;8:250-51.